Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beta globin transduced bone marrow cells - Errant Gene Therapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Beta globin transduced bone marrow cells - Errant Gene Therapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: Autologous CD34+ cells transduced with TNS9.3.55; Autologous CD34+ stem cells - EGT; Thalagen; Thalassaemia gene therapy - EGT; TNS9-3-55 transduced CD34 cells

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Errant Gene Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference; Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia
  • New Molecular Entity No

Highest Development Phases

  • No development reported Beta-thalassaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Beta-thalassaemia in USA (IV, Infusion)
  • 15 Nov 2010 Thalagen™ receives orphan drug status for Beta-thalassaemia in European Union
  • 15 Nov 2010 Thalagen™ receives orphan drug status for Beta-thalassaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top